Sustained normalization of hydrogen-positive small intestinal bacterial overgrowth after polyethylene glycol bowel

Kunihiko Yokoyama1, Kentaro Tominaga2, Yuichi Kojima1

  • 1Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-Dori, Chuo-ku, Niigata, 951-8510, Niigata, Japan.

Insights

Polyethylene glycol (PEG) bowel preparation may temporarily resolve small intestinal bacterial overgrowth (SIBO) in patients with chronic liver disease. A single case showed SIBO normalization after PEG preparation, lasting six weeks without further treatment.

Area of Science:

  • Gastroenterology
  • Hepatology
  • Microbiology

Background:

  • Small intestinal bacterial overgrowth (SIBO) is a common complication in chronic liver disease (CLD) patients with portal hypertension.
  • SIBO often persists or recurs despite conventional therapies, impacting patient quality of life.

Purpose of the Study:

  • To investigate the potential impact of polyethylene glycol (PEG)-based bowel preparations on SIBO in a patient with CLD.
  • To report a novel observation regarding the effect of transient luminal interventions on gut microbiota.

Main Methods:

  • A case report of a 44-year-old male with metabolic dysfunction-associated steatohepatitis and portal hypertension.
  • Pre- and post-colonoscopy breath testing (hydrogen and methane) to assess SIBO.
  • Standard PEG-based bowel preparation administered prior to colonoscopy.

Main Results:

  • Initial breath tests confirmed hydrogen-positive, methane-negative SIBO.
  • One week after PEG bowel preparation, breath tests normalized, indicating SIBO resolution.
  • SIBO remained resolved at six-week follow-up without additional interventions.

Conclusions:

  • This case suggests PEG bowel preparation may transiently impact small intestinal microbial composition.
  • Further research is needed to explore this phenomenon as a potential therapeutic avenue for SIBO in high-risk patients.

Related Concept Videos

Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy01:26

Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy

Sigmoidoscopy and laparoscopy are distinct medical procedures that enable physicians to internally inspect different parts of the GI tract. Although they serve different purposes, each is essential for diagnosing and, in some cases, treating various medical conditions.
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...